30 citations
,
January 2020 in “Fertility and Sterility” This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.
8 citations
,
February 2019 in “Journal of The European Academy of Dermatology and Venereology” This letter to the editor about prostaglandins in androgenetic alopecia in men and women reports no new research findings.
38 citations
,
February 2019 in “Clinical Interventions in Aging” This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.
23 citations
,
January 2019 in “International Journal of Dermatology” This review found that while finasteride may improve female pattern hair loss and hirsutism in women, more long-term studies are needed to optimize its use and assess potential consequences.
8 citations
,
January 2019 in “Clinical research and trials” This study found that long-term treatment with 1 mg/day finasteride over 10 years resulted in high efficacy and prevention of disease progression in Japanese men with androgenetic alopecia, with no serious adverse reactions reported.
11 citations
,
December 2018 in “Journal of Dermatology” This study found that finasteride 1 mg improved hair growth in 85.7% of Korean men with androgenetic alopecia over five years, with varying effectiveness depending on the type of hair loss.
15 citations
,
January 2018 in “Acta dermato-venereologica” This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.
145 citations
,
November 2017 in “Journal of The European Academy of Dermatology and Venereology” This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
6 citations
,
January 2017 in “Annals of Dermatology” In this study, Korean women with female pattern hair loss who used a combination of topical 0.025% 17α-estradiol and 3% minoxidil saw significant increases in total hair count and hair caliber over six months.
32 citations
,
July 2016 in “PubMed” This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.
50 citations
,
July 2014 in “International Journal of Clinical Pharmacology and Therapeutics” This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.
97 citations
,
January 2014 in “Journal of The American Academy of Dermatology” This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.
68 citations
,
November 2012 in “Journal of Investigative Dermatology” This study found that PGD2 inhibits hair follicle regeneration in mice through the Gpr44 receptor, suggesting that blocking PGD2 or Gpr44 may enhance skin regeneration after wounds.
29 citations
,
November 2012 in “Journal of The European Academy of Dermatology and Venereology” This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.
46 citations
,
October 2012 in “Dermatologic Clinics” This review discusses treatment options for female pattern hair loss, emphasizing the importance of early intervention and the benefits of combined therapies, but reports no new clinical results.
115 citations
,
September 2012 in “Experimental Dermatology” This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.
205 citations
,
March 2012 in “Science Translational Medicine” PGD2 stops hair growth and is higher in bald men with AGA.
35 citations
,
February 2012 in “Journal of The American Academy of Dermatology” This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.
218 citations
,
December 2011 in “Advances in Urology” This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.
198 citations
,
October 2011 in “Journal der Deutschen Dermatologischen Gesellschaft” This article discusses the development of an evidence-based guideline for treating androgenetic alopecia and reports no new research results.
81 citations
,
August 2011 in “Journal of The American Academy of Dermatology” In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.
44 citations
,
July 2011 in “Dermatologic Therapy” This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.
5 citations
,
July 2011 in “PubMed” This case report of female-pattern androgenetic alopecia found that injected bimatoprost solution did not successfully treat the condition, prompting considerations for future prostaglandin analog therapies.
100 citations
,
June 2011 in “Journal of The American Academy of Dermatology” This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.
151 citations
,
August 2010 in “British Journal of Dermatology” This guideline reviews the diagnosis of androgenetic alopecia and offers expert consensus recommendations tailored to males, females, and adolescents, but reports no new clinical results.
92 citations
,
June 2010 in “Journal of The American Academy of Dermatology” This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
140 citations
,
October 2008 in “Nature Genetics” 
212 citations
,
September 2008 in “Journal of The American Academy of Dermatology” This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.
142 citations
,
August 2007 in “Journal of The American Academy of Dermatology” This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.
125 citations
,
May 2007 in “Journal of The American Academy of Dermatology” This study describes the development of the BASP classification system, providing a universal and systematic approach for classifying pattern hair loss in both men and women.
195 citations
,
June 2005 in “American Journal of Human Genetics” Genetic variation in the androgen receptor gene mainly causes early-onset hair loss, with maternal inheritance playing a key role.
219 citations
,
March 2004 in “Journal of The American Academy of Dermatology” In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
104 citations
,
October 1999 in “The Journal of Urology” This study concluded that daily treatment with 1 mg finasteride did not affect spermatogenesis or semen production in young men and had small, reversible effects on prostate volume and serum PSA.
100 citations
,
September 1999 in “British Journal of Dermatology” This study suggests that finasteride's effect on promoting hair growth in men with androgenetic alopecia may be due to its inhibition of 5aR2 localized in hair follicles.
227 citations
,
January 1998 in “Journal of Endocrinology” This study found that dermal papilla cells from balding scalp hair follicles have significantly higher levels of androgen receptors than those from non-balding follicles, supporting their in vivo androgen response.
124 citations
,
April 1992 in “Journal of Endocrinology/Journal of endocrinology” This study observed that cells from androgen-sensitive areas like the beard and scrotum showed higher androgen receptor levels compared to those from non-balding scalp areas, supporting the role of dermal papilla in follicle growth responses to androgens.
31 citations
,
October 1971 in “Steroids” This study found that human beard hair follicles metabolize dehydroepiandrosterone into various compounds at significantly higher rates than those reported for human skin, suggesting unique metabolic processes in hair follicles.
